Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Filings indexed 1,129 across all filing types
Latest filing 2021-02-25 Capital/Financing Update
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Apellis Pharmaceuticals, Inc. It registers additional shares under stock incentive plans. The document includes details about the securities to be registered, the plans under which shares are issued, and exhibits such as the stock incentive plans and legal opinions. Form S-8 is a registration statement used for securities issued under employee benefit plans and is a type of capital/financing update related to share issuance. It is not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2021-02-25 English
10-K
Annual Report FY 2020
2021-02-25 English
PRIMARY DOCUMENT
Director's Dealing
2021-02-17 English
PRIMARY DOCUMENT
Director's Dealing
2021-02-17 English
SC 13G/A
Major Shareholding Notification
2021-02-16 English
APELLIS PHARMACEUTICALS, INC.
Major Shareholding Notification
2021-02-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.